{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,16]],"date-time":"2026-09-16T00:40:30Z","timestamp":1789519230229,"version":"build-2803163510"},"reference-count":46,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[1990,5,1]],"date-time":"1990-05-01T00:00:00Z","timestamp":641520000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[1990,5,1]],"date-time":"1990-05-01T00:00:00Z","timestamp":641520000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Invest New Drugs"],"published-print":{"date-parts":[[1990,5]]},"DOI":"10.1007\/bf00177266","type":"journal-article","created":{"date-parts":[[2004,8,22]],"date-time":"2004-08-22T08:15:28Z","timestamp":1093162528000},"page":"227-238","source":"Crossref","is-referenced-by-count":16,"title":["Clinical toxicity associated with tiazofurin"],"prefix":"10.1007","volume":"8","author":[{"given":"Jean L.","family":"Grem","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Larry","family":"Rubinstein","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Susan A.","family":"King","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bruce D.","family":"Cheson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael J.","family":"Hawkins","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dale D.","family":"Shoemaker","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","reference":[{"key":"BF00177266_CR1","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1007\/BF00173791","volume":"2","author":"PJ O'Dwyer","year":"1984","unstructured":"O'Dwyer PJ, Shoemaker DD, Jayaram HN, Johns DG, Cooney DA, Marsoni S, Malspeis L, Plowman J, Davignon JP, Davis RD: Tiazofurin: A new antitumor agent. Invest New Drugs 2: 79\u201384, 1984","journal-title":"Invest New Drugs"},{"key":"BF00177266_CR2","first-page":"3869","volume":"31","author":"HN Jayaram","year":"1982","unstructured":"Jayaram HN, Smith AL, Glazer RI, Johns DG, Cooney DA: Studies on the mechanism of action of 2-beta-D-ribofuranosylthiazole-4-carboxamide (NSC 286193)-II. Biochem Pharmacol 31: 3869\u20133845, 1982","journal-title":"Biochem Pharmacol"},{"key":"BF00177266_CR3","doi-asserted-by":"crossref","first-page":"272","DOI":"10.1016\/0065-2571(83)90019-5","volume":"21","author":"DA Cooney","year":"1983","unstructured":"Cooney DA, Jayaram HN, Glazer RI et al.: Studies on the mechanism of action of tiazofurin metabolism to an analog of NAD with potent IMP-dehydrogenase-inhibitory activity. Adv Enz Regul 21: 272\u2013303, 1983","journal-title":"Adv Enz Regul"},{"key":"BF00177266_CR4","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1016\/0065-2571(85)90069-X","volume":"24","author":"G Weber","year":"1985","unstructured":"Weber G, Natsumeda Y, Pillwein K: Targets and markers of selective action of tiazofurin. Adv Enz Regul 24: 45\u201365, 1985","journal-title":"Adv Enz Regul"},{"key":"BF00177266_CR5","first-page":"5512","volume":"45","author":"HJ Lee","year":"1985","unstructured":"Lee HJ, Pawlak K, Nguyen BT, Robins RK, Sadee W: Biochemical differences among four inosinate dehydrogenase inhibitors, mycophenolic acid, ribavirin, tiazofurin, and selenazofurin, studied in mouse lymphoma cell culture. Cancer Res 45: 5512\u20135520, 1985","journal-title":"Cancer Res"},{"key":"BF00177266_CR6","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/0304-3835(85)90085-0","volume":"28","author":"A Monks","year":"1985","unstructured":"Monks A, Marquez VE, Mao DT, Cysyk RL: Uptake of 2-beta-D-ribofuranosylthiazole-4-carboxamide (tiazofurin) and analogues by the facilitated transport mechanism of erythrocytes. Cancer Lett 28: 1\u20138, 1985","journal-title":"Cancer Lett"},{"key":"BF00177266_CR7","doi-asserted-by":"crossref","first-page":"1109","DOI":"10.1016\/0006-2952(85)90617-3","volume":"34","author":"TJ Boritzki","year":"1985","unstructured":"Boritzki TJ, Berry DA, Besserer JA, Cook PD, Fry DW, Leopold WR, Jackson RC: Biochemical and antitumor activity of tiazofurin and its selenium analog (2-beta-D-ribofuranosyl-4-selenacarboxamide). Biochem Pharmacol 34: 1109\u20131114, 1985","journal-title":"Biochem Pharmacol"},{"key":"BF00177266_CR8","doi-asserted-by":"crossref","first-page":"702","DOI":"10.1172\/JCI111750","volume":"75","author":"NA Berger","year":"1985","unstructured":"Berger NA, Berger SJ, Catino DM, Petzold SJ, Robins RK: Modulation of nicotinamide adenine dinucleotide and poly (adenosine diphosphoribose) metabolism by the synthetic \u201cC\u201d nucleoside analogs, tiazofurin and selenazofurin. A new strategy for cancer chemotherapy. J Clin Invest 75: 702\u2013709, 1985","journal-title":"J Clin Invest"},{"key":"BF00177266_CR9","first-page":"4","volume":"27","author":"BR Miller","year":"1986","unstructured":"Miller BR, Affigne SM: Purine nucleoside phosphorylase and adenosine deaminase activity in the spleens of C57BL\/6 mice bearing Lewis lung carcinoma \u2014 effect of tiazofurin. Proc Am Assoc Cancer Res 27: 4, 1986 (Abstr)","journal-title":"Proc Am Assoc Cancer Res"},{"key":"BF00177266_CR10","doi-asserted-by":"crossref","first-page":"2029","DOI":"10.1016\/0006-2952(86)90737-9","volume":"35","author":"HN Jayaram","year":"1986","unstructured":"Jayaram HN, Pillwein K, Nichols CR, Hoffman R, Weber G: Selective sensitivity to tiazofurin of human leukemic cells. Biochem Pharmacol 35: 2029\u20132032, 1986","journal-title":"Biochem Pharmacol"},{"key":"BF00177266_CR11","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1007\/978-1-4613-2061-6_3","volume":"36","author":"GS Ahluwalia","year":"1987","unstructured":"Ahluwalia GS, Jayaram HN, Coony DA: Metabolites of tiazofurin as mediators of its biochemical and pharmacologic effects. Cancer Treat Res 36: 63\u2013102, 1987","journal-title":"Cancer Treat Res"},{"key":"BF00177266_CR12","doi-asserted-by":"crossref","first-page":"2193","DOI":"10.1021\/bi00406a057","volume":"27","author":"Y Yamada","year":"1988","unstructured":"Yamada Y, Natsumeda Y, Weber G: Action of the active metabolites of tiazofurin and ribavirin on purified IMP dehydrogenase. Biochemistry 27: 2193\u20132196, 1988","journal-title":"Biochemistry"},{"key":"BF00177266_CR13","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1016\/0065-2571(85)90070-6","volume":"24","author":"HN Jayaram","year":"1986","unstructured":"Jayaram HN: Biochemical mechanisms of resistance to tiazofurin. Adv Enz Regul 24: 67\u201389, 1986","journal-title":"Adv Enz Regul"},{"key":"BF00177266_CR14","doi-asserted-by":"crossref","first-page":"634","DOI":"10.1182\/blood.V69.2.634.634","volume":"69","author":"RD Knight","year":"1987","unstructured":"Knight RD, Mangum J, Lucas DL, Cooney DA, Khan EC, Wright DG: Inosine monophosphate dehydrogenase and myeloid cell maturation. Blood 69: 634\u2013639, 1987","journal-title":"Blood"},{"key":"BF00177266_CR15","first-page":"36","volume":"3","author":"J Neidhart","year":"1984","unstructured":"Neidhart J, Metz E, Gochnour D, Dallaire B, Grillo-Lopez A, Malspeis L: Phase I study of tiazofurin (2-beta-D-ribofuranosyl-4-thiazole-carboxamide; NSC 286193). Proc Am Soc Clin Oncol 3: 36, 1984 (Abstr)","journal-title":"Proc Am Soc Clin Oncol"},{"key":"BF00177266_CR16","first-page":"5169","volume":"45","author":"FM Balis","year":"1985","unstructured":"Balis FM, Lange BJ, Packer RJ, Holcenberg JS, Ettinger LJ, Sallan SE, Heideman RL, Zimm S, Smithson WA, Cogliano-Shutta NA et al.: Pediatric phase I trial and pharmacokinetic study of tiazofurin (NSC 286193). Cancer Res45: 5169\u20135172, 1985","journal-title":"Cancer Res"},{"key":"BF00177266_CR17","first-page":"48","volume":"4","author":"JA Maroun","year":"1985","unstructured":"Maroun JA, Green R, Stewart DJ: Phase I study of tiazofurin (2-beta-D-ribofuranosylthiazole-4-carboxamide). Proc Am Soc Clin Oncol 4: 48, 1985 (Abstr)","journal-title":"Proc Am Soc Clin Oncol"},{"key":"BF00177266_CR18","first-page":"2859","volume":"45","author":"TJ Melink","year":"1985","unstructured":"Melink TJ, Von Hoff DD, Kuhn JG, Hersh MR, Sternson LA, Patten TF, Siegler R, Boldt DH, Clark GM: Phase I evaluation and pharmacokinetics of tiazofurin (2-beta-D-ribofuranosylthiazole-4-carboxamide, NSC 286193). Cancer Res 45: 2859\u20132865, 1985","journal-title":"Cancer Res"},{"key":"BF00177266_CR19","first-page":"188","volume":"26","author":"VE Currie","year":"1985","unstructured":"Currie VE, Budman D, Hancock C, Lokos G, Williams L, Bauer T, Parente R, Young C: Phase I and clinical pharmacologic evaluation of tiazofurin by an intermittent schedule. Proc Am Assoc Cancer Res 26: 188, 1985 (Abstr)","journal-title":"Proc Am Assoc Cancer Res"},{"key":"BF00177266_CR20","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1007\/BF00173513","volume":"4","author":"RM Green","year":"1986","unstructured":"Green RM, Stewart DJ, Maroun JA: Clinical pharmacology of tiazofurin (2-beta-D-ribofuranosylthiazole-4-carboxamide, NSC 286193). Invest New Drugs 4: 387\u2013394, 1986","journal-title":"Invest New Drugs"},{"key":"BF00177266_CR21","first-page":"173","volume":"27","author":"T Melink","year":"1986","unstructured":"Melink T, Von Hoff D, Phillips J, Sarosy G, Grever M, Jayaram H, Whitecar J: Phase I trial and biochemical evaluation of tiazofurin on a weekly schedule. Proc Am Assoc Cancer Res 27: 173, 1986 (Abstr)","journal-title":"Proc Am Assoc Cancer Res"},{"key":"BF00177266_CR22","first-page":"141","volume":"71","author":"JD Roberts","year":"1987","unstructured":"Roberts JD, Stewart JA, McCormack JJ, Krakoff IR, Culham CA, Hartshorn JN, Newman RA, Haugh LD, Young JA: Phase I trial of tiazofurin administered by i.v. bolus daily for 5 days, with pharmacokinetic evaluation. Cancer Treat Rep 71: 141\u2013149, 1987","journal-title":"Cancer Treat Rep"},{"key":"BF00177266_CR23","first-page":"2853","volume":"45","author":"DL Trump","year":"1985","unstructured":"Trump DL, Tutsch KD, Koeller JM, Tormey DC: Phase I clinical study with pharmacokinetic analysis of 2-beta-D-ribofuranosylthiazole-4-carboxamide (NSC 286193) administered as a five-day infusion. Cancer Res 45: 2853\u20132858, 1985","journal-title":"Cancer Res"},{"key":"BF00177266_CR24","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1007\/BF00170757","volume":"3","author":"G Batist","year":"1985","unstructured":"Batist G, Klecker RW Jr, Jauaram HN, Jenkins JF, Grygiel J, Ihde DC, Eddy JL, Fine RL, Kerr IG, Collins JM: Phase I and pharmacokinetic study of tiazofurin (NSC 286193) administered by continuous infusion. Invest New Drugs 3: 349\u2013355, 1985","journal-title":"Invest New Drugs"},{"key":"BF00177266_CR25","first-page":"160","volume":"16","author":"D Raghaven","year":"1986","unstructured":"Raghaven D, Bishop J, Sampson D, Grygiel J, Woods R, Coates A, Fox R: Phase I and pharmacokinetic study of tiazofurin (NSC 286193) administered by 5-day continuous infusion. Cancer Chemother Pharmacol 16: 160\u2013164, 1986","journal-title":"Cancer Chemother Pharmacol"},{"key":"BF00177266_CR26","first-page":"253","volume":"7","author":"R Goldberg","year":"1988","unstructured":"Goldberg R, Ahlgren J: Treatment of metastatic malignant melanoma with tiazofurin: A phase II study. Proc Am Soc Clin Oncol 7: 253, 1988 (Abstr)","journal-title":"Proc Am Soc Clin Oncol"},{"key":"BF00177266_CR27","first-page":"425","volume":"71","author":"IW Dimery","year":"1987","unstructured":"Dimery IW, Neidhart JA, McCarthy K, Krakoff IH, Hong WK: Phase II trial of tiazofurin in recurrent squamous cell carcinoma of the head and neck. Cancer Treat Rep 71: 425\u2013426, 1987","journal-title":"Cancer Treat Rep"},{"key":"BF00177266_CR28","first-page":"1297","volume":"71","author":"JA Maroun","year":"1987","unstructured":"Maroun JA, Eisenhauer E, Cripps C, Maksymiuk A: Phase II study of tiazofurin in colorectal cancer: A NationalCancer Institute of Canada study. Cancer Treat Rep 71: 1297\u20131298, 1987","journal-title":"Cancer Treat Rep"},{"key":"BF00177266_CR29","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1007\/BF00175401","volume":"6","author":"PY Holoye","year":"1988","unstructured":"Holoye PY, Carr DT, Dhingra HM, Glisson BS, Lee JS, Murphy WK, Umsawasdi T, Jeffries D: Phase II study of tiazofurin (286193) in the treatment of advanced small cell bronchogenic carcinoma. Invest New Drugs 6: 217\u2013218, 1988","journal-title":"Invest New Drugs"},{"key":"BF00177266_CR30","first-page":"4988","volume":"47","author":"GJ Tricot","year":"1987","unstructured":"Tricot GJ, Jayaram HN, Nichols CR, Pennington K, Lapis E, Weber G, Hoffman R: Hematological and biochemical action of tiazofurin (NSC 286193) in a case of refractory acute myeloid leukemia. Cancer Res 47: 4988\u20134991, 1987","journal-title":"Cancer Res"},{"key":"BF00177266_CR31","first-page":"210","volume":"29","author":"GJ Tricot","year":"1988","unstructured":"Tricot GJ, Jayaram HN, Weber G, Hoffman R: Tiazofurin is a potent antiproliferative agent and induces differentiation in patients with leukemia. Proc Am Assoc Cancer Res 29: 210, 1988 (Abstr)","journal-title":"Proc Am Assoc Cancer Res"},{"key":"BF00177266_CR32","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1016\/0065-2571(88)90029-5","volume":"27","author":"G Weber","year":"1988","unstructured":"Weber G, Jayaram HN, Lapis E, Natsumeda Y, Yamada Y, Yamaju Y, Tricot GJ, Hoffman R: Enzyme-patterntargeted chemotherapy with tiazofurin and allopurinol in human leukemia. Adv Enz Regul 27: 405\u2013433, 1988","journal-title":"Adv Enz Regul"},{"key":"BF00177266_CR33","volume-title":"Statistical methods for rates and proportions","author":"JL Fleiss","year":"1981","unstructured":"Fleiss JL: Statistical methods for rates and proportions. John Wiley and Sons, New York, 1981"},{"key":"BF00177266_CR34","unstructured":"National Cancer Institute, Division of Cancer Treatment, Clinical Brochure: Tiazofurin (NSC 286193), Bethesda, MD, 1982"},{"key":"BF00177266_CR35","first-page":"307","volume":"27","author":"L Balducci","year":"1986","unstructured":"Balducci L, Thigpen JT, Hardy C: Hemopoietic effects of tiazofurin in normal and tumor bearing animals. Proc Am Assoc Cancer Res 27: 307, 1986 (Abstr)","journal-title":"Proc Am Assoc Cancer Res"},{"key":"BF00177266_CR36","first-page":"2037","volume":"45","author":"JJ Grygiel","year":"1985","unstructured":"Grygiel JJ, Balis FM, Collins JM, Lester CM, Poplack DG: Pharmacokinetics of tiazofurin in the plasma and cerebrospinal fluid of rehesus monkeys. Cancer Res 45: 2037\u20132039, 1985","journal-title":"Cancer Res"},{"key":"BF00177266_CR37","first-page":"288","volume":"2","author":"RM Green","year":"1984","unstructured":"Green RM, Hugenholtz H, Richard M, Dennery J, Hopkins H, Thibault M, Stewart DJ: Human central nervous system pharmacology of tiazofurin. J Neurooncol 2: 288, 1984","journal-title":"J Neurooncol"},{"key":"BF00177266_CR38","first-page":"165","volume":"12","author":"ST Arnold","year":"1984","unstructured":"Arnold ST, Jayaram HN, Harper GR, Litterst CL, Malspies L, DeSouza JV, Staubus AE, Ahluwalia GS, Wison YA, Cooney DA, Johns DG: The disposition and metabolism of tiazofurin in rodents, rabbits and dogs. Drug Metab Dispos 12: 165\u2013173, 1984","journal-title":"Drug Metab Dispos"},{"key":"BF00177266_CR39","first-page":"669","volume-title":"Fourth Conference on Human Tumor Cloning","author":"B Lathan","year":"1984","unstructured":"Lathan B, Von Hoff DD, Melink TJ, Kisner DL: Screening of Phase I drugs in the human tumor cloning system to pinpoint areas of emphasis in phase II studies: Human Tumor Cloning. Fourth Conference on Human Tumor Cloning. Salmon SE, Trent JM (eds) Orlando, Florida, Grune and Stratton, 1984, p 669"},{"key":"BF00177266_CR40","first-page":"375","volume":"25","author":"TJ Melink","year":"1984","unstructured":"Melink TJ, Von Hoff DD, Clark GM, Coltman CA Jr: Antitumor activity of tiazofurin in a human tumor cloning system. Proc Am Assoc Cancer Res 25: 375, 1984 (Abstr)","journal-title":"Proc Am Assoc Cancer Res"},{"key":"BF00177266_CR41","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1172\/JCI111671","volume":"75","author":"DN Carney","year":"1985","unstructured":"Carney DN, Ahluwalia GS, Jayaram HN, Coomey DA, Johns DG: Relationship between the cytotoxicity of tiazofurin and its metabolism by cultured human lung cancer cells. Clin Invest 75: 175\u2013182, 1985","journal-title":"Clin Invest"},{"key":"BF00177266_CR42","first-page":"57","volume":"7","author":"G Locker","year":"1988","unstructured":"Locker G, Khandekar J, Knop R, Kram J, Carro G, Block T, French S, Tuteur D: Illinois cancer council phase I trial of weekly intravenous aminothiadiazole. Proc Am Soc Clin Oncol 7: 57, 1988 (Abstr)","journal-title":"Proc Am Soc Clin Oncol"},{"key":"BF00177266_CR43","first-page":"35","volume-title":"Recent Developments in Cancer Chemotherapy","author":"JD Stoeckler","year":"1984","unstructured":"Stoeckler JD: Purine nucleoside phosphorylase: A target for chemotherapy. In: Glazer R (ed) Recent Developments in Cancer Chemotherapy. CRS Press, Boca Raton, FL, 1984 pp 35\u201360"},{"key":"BF00177266_CR44","doi-asserted-by":"crossref","first-page":"719","DOI":"10.1016\/S0308-2261(82)80013-1","volume":"11","author":"AV Hoffbrand","year":"1982","unstructured":"Hoffbrand AV, Ma DD, Webster AD: Enzyme patterns in normal lymphocyte subpopulations, lymphoid leukaemias and immunodeficiency syndromes. Clin Haematol 11: 719\u2013741, 1982","journal-title":"Clin Haematol"},{"key":"BF00177266_CR45","first-page":"2498","volume":"47","author":"A Begleiter","year":"1987","unstructured":"Begleiter A, Glazer RI, Israels LG, Pugh L, Johnston JB: Induction of DNA strand breaks in chronic lymphocytic leukemia following treatment with 2\u2032deoxycoformycin in vivo and in vitro. Cancer Res 47: 2498\u20132503, 1987","journal-title":"Cancer Res"},{"key":"BF00177266_CR46","first-page":"21","volume":"27","author":"PM Brager","year":"1986","unstructured":"Brager PM, Grever MR: 9-beta-D-arabinofuranosyl-2-fluo-roadenine reduces NAD in normal lymphocytes and neoplastic cells in CLL. Proc Am Assoc Cancer Res 27: 21, 1986 (Abstr)","journal-title":"Proc Am Assoc Cancer Res"}],"container-title":["Investigational New Drugs"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/BF00177266.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/BF00177266\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/BF00177266","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/BF00177266.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,3,11]],"date-time":"2023-03-11T18:18:27Z","timestamp":1678558707000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/BF00177266"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[1990,5]]},"references-count":46,"journal-issue":{"issue":"2","published-print":{"date-parts":[[1990,5]]}},"alternative-id":["BF00177266"],"URL":"https:\/\/doi.org\/10.1007\/bf00177266","relation":{},"ISSN":["0167-6997","1573-0646"],"issn-type":[{"value":"0167-6997","type":"print"},{"value":"1573-0646","type":"electronic"}],"subject":[],"published":{"date-parts":[[1990,5]]}}}